0
Edesa Biotech, Inc. Banner Image

Edesa Biotech, Inc.

  • Ticker EDSA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Edesa Biotech, Inc. Logo Image
  • 11-50 Employees
  • Based in Markham, Ontario
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Their most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a PhaseMore 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. They also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Edesa Biotech, Inc.

Most Recent Annual Report

Edesa Biotech, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Edesa Biotech, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!